Press Releases :: ContraFect Corporation (CFRX)

Press Releases

Investors & Media

ContraFect Corporation Provides Update on CF-301 Phase 1 Trial

August 11, 2015

ContraFect Corporation to Announce Second Quarter 2015 Results on August 13, 2015

August 6, 2015

ContraFect Corporation Announces Issuance of Key Patent Covering Novel Lysin Technology

July 17, 2015

ContraFect Corporation Announces $20,000,000 Private Placement

June 11, 2015

ContraFect Corporation Announces First Healthy Volunteer Dosed With CF-301

May 21, 2015

ContraFect Corporation Adds Former Cubist Executive Steven C. Gilman, PhD, to Board of Directors as Executive Chairman

May 20, 2015

ContraFect Corporation Announces First Quarter 2015 Results

May 15, 2015

ContraFect Corporation Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA

April 29, 2015

ContraFect Corporation Announces Fourth Quarter and Full Year 2014 Results

April 6, 2015

ContraFect to Present at 27th Annual ROTH Conference

March 3, 2015